No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

SCI Pharmtech, Inc., founded in 1987 and based in Taoyuan City, Taiwan, specializes in the comprehensive lifecycle of pharmaceutical components. The company's core operations involve the research and development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs), chemical intermediates, and specialty chemicals. Its extensive portfolio of APIs includes critical compounds such as Articaine HCl, Atomoxetine HCl, Bisoprolol Fumarate, Brinzolamide, Cannabidiol, and Dexmethylphenidate HCl, among many others. Additionally, SCI Pharmtech produces a wide array of intermediate products, featuring substances like Azetidin-3-ol hydrogenchloride, Diethyl Isobutyl Malonate, Pyrogallolaldehyde, and various specialized esters and alcohols, which serve as essential building blocks in chemical synthesis. Beyond its standard product lines, the company also offers custom manufacturing services tailored to specific client needs. SCI Pharmtech maintains a robust international presence, distributing its products to significant markets across the globe, including Italy, China, the United States, Germany, Taiwan, Switzerland, Spain, Japan, and the Netherlands.

• Journey Medical Corporation
• Boditech Med Inc.
• Canopy Growth Corporation
• Jilin Province Huinan Changlong Bio-pharmacy Company Limited
• Kwang Dong Pharmaceutical Co., Ltd.
• Korea United Pharm Inc.
• Lifecore Biomedical, Inc.
• Cardiol Therapeutics Inc.